Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP - 1 Nov 2020

Salim Adnan, Farooq Muhammad Omer, Mengal Farhan Ul Amin, Malik Kashif

Abstract excerpt

The objective of this study was to ascertain the safety and efficacy of sofosbuvir in patients undergoing hemodialysis. Twenty-three HCV infected patients undergoing hemodialysis were included. Sofosbuvir was administered in combinations with ribavirin, daclatasvir and ledipasvir for 12-24 weeks. Viral response was checked at the end and 12 weeks after completing therapy. Twenty-one (91.3%) were of genotype 3 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Renal Dialysis

Share to Ribavirin

Share to Sofosbuvir

Source

Identifiers

PMID: 33222748
DOI: 10.29271/jcpsp.2020.11.1230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.PMID 33222748Read ↗

Sofosbuvir-Based HCV Treatment in Maintenance Hemodialysis Patients: A Single-Center Study.Semantic proximity Read ↗

Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.Semantic proximity Read ↗

Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis.Semantic proximity Read ↗

Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.Semantic proximity Read ↗

Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis.Semantic proximity Read ↗

Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.Semantic proximity Read ↗

Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.Semantic proximity Read ↗

Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection.Semantic proximity Read ↗

Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and compensated cirrhosisSemantic proximity Read ↗

Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.Semantic proximity Read ↗

Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.